| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥3970.4B | ¥3745.6B | +6.0% |
| Operating Income | ¥882.9B | ¥707.5B | +24.8% |
| Profit Before Tax | ¥893.8B | ¥720.4B | +24.1% |
| Net Income | ¥688.7B | ¥565.3B | +21.8% |
| ROE | 8.1% | 7.2% | - |
FY2026 Q3 results: Revenue 397.0B yen (YoY +6.0%), Operating Income 88.3B yen (YoY +24.8%), Ordinary Income data not separately disclosed, Net Income 68.9B yen (YoY +21.8%). Operating margin expanded significantly to 22.2% from 18.9% in the prior year, reflecting a 330 basis point improvement driven by gross margin maintenance at 72.6% and effective SG&A cost control. Net profit margin rose to 17.4% from 15.1%, up 230 basis points, demonstrating strong operating leverage as profit growth substantially outpaced revenue growth. Against full-year guidance of 490.0B yen revenue and 85.0B yen operating income, the company has achieved 81% revenue progress and 104% operating income progress, indicating upside potential on profitability metrics. R&D expenditure of 104.6B yen represents 26.3% of revenue, underscoring continued commitment to pipeline development.
[Profitability] ROE of 8.2% reflects improving earnings power supported by net profit margin of 17.4% (up 230bp YoY), asset turnover of 0.366, and financial leverage of 1.28. Operating margin of 22.2% represents a substantial 330bp expansion from 18.9% in the prior year, driven by product mix optimization and SG&A efficiency gains. Gross margin maintained at 72.6% with gross profit of 288.4B yen. R&D intensity of 26.3% indicates strong research-oriented investment posture. [Cash Quality] Cash and equivalents of 188.4B yen provide 5.95x coverage of short-term borrowings of 31.6B yen, ensuring robust liquidity. Operating cash flow of 86.6B yen represents 1.26x net income, confirming cash-backed earnings quality with an accruals ratio of negative 1.6%. [Investment Efficiency] Total asset turnover of 0.366 times, with inventory turnover days of 222 days indicating room for working capital optimization. Receivables turnover of 92 days and payables turnover of 70 days reflect balanced trade credit management. Intangible assets of 369.2B yen (34.0% of total assets) represent significant pipeline and IP investments requiring ongoing performance monitoring. [Financial Health] Equity ratio of 77.4% demonstrates conservative capitalization with debt-to-equity of 0.135. Total interest-bearing debt of 114.1B yen declined from prior period, with long-term borrowings decreasing 22.5B yen to 82.5B yen. Current ratio of 6.84x and interest coverage of approximately 36.7x (EBIT to interest expense) indicate strong financial stability. Income tax payable increased 14.4B yen to 18.4B yen, reflecting higher profitability and timing of tax settlements.
Operating cash flow of 86.6B yen represents 1.26x net income of 68.9B yen, confirming high-quality earnings conversion. Working capital contributed positively with inventory changes adding 10.1B yen and other working capital items contributing 9.5B yen, reflecting efficient capital management despite inventory days remaining elevated at 222 days. Investing cash flow reflected capital expenditure of 4.9B yen and substantial intangible asset acquisitions of 47.0B yen, the latter representing strategic investments in product rights and technology platforms for future growth. Free cash flow of 42.6B yen provided coverage of 1.07x for dividend payments of 36.4B yen and capital expenditure combined, demonstrating sustainable cash generation capacity. Financing activities included interest payments of 1.6B yen, which remain modest relative to operating cash generation. Cash and deposits increased to 188.4B yen, providing substantial liquidity buffer of 5.95x short-term debt and supporting financial flexibility for ongoing R&D investments and potential business development activities.
Operating income of 88.3B yen primarily drives profitability, with non-operating items contributing a net positive of approximately 1.1B yen comprising financial income of 3.5B yen partially offset by financial expenses of 2.4B yen. Non-operating income represents approximately 0.9% of revenue and consists mainly of interest and dividend income alongside equity method investment gains and foreign exchange adjustments. The modest contribution of non-operating items indicates that earnings quality is firmly grounded in core pharmaceutical operations. Operating cash flow exceeding net income at 1.26x confirms robust cash realization, while the negative accruals ratio of negative 1.6% indicates earnings are not inflated by aggressive accounting estimates. The effective tax rate of 22.9% aligns with corporate tax norms and shows stability. Comprehensive income of 92.4B yen exceeded net income, benefiting from positive other comprehensive income contributions including fair value adjustments and pension remeasurement gains, though these non-cash items do not affect core earnings sustainability.
Pipeline execution risk remains significant given R&D expenditure of 104.6B yen (26.3% of revenue) and intangible asset acquisitions of 47.0B yen, with future revenue dependent on successful clinical development, regulatory approvals, and commercial launch of investigational products. Inventory management efficiency warrants monitoring as inventory turnover days of 222 days substantially exceeds operational norms, though this partly reflects regulatory requirements for supply continuity and quality assurance, elevated inventory levels tie up working capital and create obsolescence risk if demand patterns shift or products face shelf-life constraints. Intangible asset concentration at 369.2B yen (34.0% of total assets) including goodwill of 22.2B yen exposes the balance sheet to impairment risk if acquired rights or in-process R&D fail to achieve projected commercial outcomes, requiring rigorous ongoing assessment of asset recoverability and value realization timelines.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating margin 22.2% significantly outperforms industry median of negative 218.2% (Q3 2025, n=13 companies), placing the company in the top tier of pharmaceutical profitability. Net profit margin of 17.4% contrasts sharply with industry median of negative 216.8%, reflecting sustainable core business profitability versus industry peers facing restructuring or development-stage losses. ROE of 8.2% substantially exceeds industry median of negative 35.8%, demonstrating superior capital efficiency and earnings generation.
Financial Health: Equity ratio of 77.4% compares favorably to industry median of 67.8% (IQR 62.1-79.1%), indicating conservative balance sheet positioning in the upper quartile. Current ratio of 6.84x surpasses industry median of 6.62x (IQR 4.66-9.18x), confirming strong liquidity relative to sector norms.
Efficiency: Asset turnover of 0.366 exceeds industry median of 0.17 (IQR 0.05-0.24), reflecting more productive asset utilization and revenue generation per yen of assets deployed. Inventory turnover of 222 days compares favorably to industry median of 282 days (IQR 146-302 days), though absolute level still indicates opportunity for further working capital optimization. Revenue growth of 6.0% outperforms industry median of negative 12.5% (IQR negative 22.1% to negative 2.5%), positioning the company among growth leaders in a contracting sector environment.
※ Industry: Pharmaceuticals (13 companies for most metrics), Comparison: FY2025 Q3 period medians and interquartile ranges, Source: Proprietary analysis
Margin expansion trajectory shows operating leverage gains with operating margin improving 330bp to 22.2% while maintaining high R&D intensity of 26.3%, indicating the company has achieved scale efficiencies in SG&A without compromising future growth investment, a combination that distinguishes it from industry peers facing profitability pressures. The 104% operating income progress versus 81% revenue progress against full-year guidance signals potential for upside revision or conservative budgeting for Q4 variable costs including research milestones and business development activities. Strong cash conversion with operating CF at 1.26x net income and negative accruals ratio of negative 1.6% confirms earnings quality is supported by genuine cash generation rather than accounting accruals, providing confidence in sustainability of reported profitability. Strategic capital allocation balances shareholder returns with growth investment, as free cash flow of 42.6B yen covers dividend payments of 36.4B yen at a payout ratio of 57.9% while simultaneously funding substantial intangible asset acquisitions of 47.0B yen, positioning the pipeline for medium-term revenue drivers while maintaining conservative leverage at 11.9% debt-to-capital and 77.4% equity ratio.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.